Kinaset Therapeutics is focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases. Their lead clinical candidate, frevecitinib (KN-002), is a novel and non-invasive anti-inflammatory to treat all patients with severe asthma.

Kinaset Therapeutics is focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases. Their lead clinical candidate, frevecitinib (KN-002), is a novel and non-invasive anti-inflammatory to treat all patients with severe asthma.